LKQ's ERP Crisis Deepens as CEO Exits and Europe Revenue Collapses

What happened

LKQ Corporation shares fell sharply again as investors reacted to the immediate departure of its CEO and continued problems with the company's European ERP system implementation. This follows a 14% drop on July 30, 2026, when management first acknowledged ERP disruptions but assured investors that operations had normalized. Third-quarter results revealed Europe organic parts-and-services revenue fell 9.8% and segment EBITDA margin collapsed to 4.6% from 10.0% a year earlier, prompting the board to withdraw full-year guidance. In response, the board replaced the CEO, changed Europe leadership, engaged Alvarez & Marsal, and suspended the strategic review and Specialty sale process. The stock now trades at $17.8, down 42% over the past year, but lacks proof that improved service levels will translate into regained revenue and margin.

Implication

Investors should treat the current price as reflecting some, but not all, of the deterioration in Europe. The valuation at 15x P/E and 6.3x EV/EBITDA is not demanding, but without operational proof the risk-reward is poor. Near term, monitor whether new CEO Sal Abbate sets measurable recovery targets and whether Germany's OTIF sustains in the high-90s while U.K. and Benelux stop losing share. Wait for signs that service improvements are converting into order recovery and that Europe margin is climbing back above 5%. A better entry appears below $16, or after Q1 2027 confirms Europe organic decline has narrowed materially from -9.8% and margin is recovering. Until then, the stock remains a show-me story with downside to $14 if customer losses persist.

Thesis delta

The thesis shifts from a temporary ERP disruption to a structural execution failure and potential market share loss in Europe. The board's decisive actions and the magnitude of the revenue and margin collapse lower conviction, prompting a WAIT rating with tighter entry criteria. If Europe revenue fails to inflect by Q1 2027, the bear case of $14 becomes increasingly likely.